G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) – Yahoo Finance

by

  1. G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) Yahoo Finance
  2. GTHX stock falls on decision to halt colorectal cancer trial (NASDAQ:GTHX) Seeking Alpha
  3. Pharma Stock Hits Record Low Due to Pulled Study Schaeffers Research
  4. G1 Therapeutics to halt drug trial in colon cancer, shares plunge Reuters.com
  5. Cosela/Immunochemotherapy Trial for Colorectal Cancer Stopped for Limited Anti-Tumor Efficacy Data Curetoday.com
  6. View Full Coverage on Google News

Read original article here

Leave a Comment